Short answer
CareDx, Inc. (CDNA) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Q4 2025 earnings results announced Feb 24, 2026: full financials in Exhibit 99.1.
CareDx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings results announced Feb 24, 2026: full financials in Exhibit 99.1
- Period covered: quarter ended December 31, 2025
- No figures disclosed in filing body: all metrics (revenue, earnings) contained in attached press release
Item 5.02 · Departure/Election of Directors or Officers
- CFO Nathan Smith resigned effective Feb 25, 2026 for personal reasons: no disagreement over financials or disclosures
- COO Keith Kennedy immediately promoted to dual CFO/COO role effective Feb 26, 2026: internal succession limits leadership disruption
- Smith severance: 9 months base salary (lump sum) + $91,643 2025 bonus + 9 months COBRA + 5,840 RSUs vested pro rata
- Kennedy brings prior CFO experience at Veracyte and PharmaLogic; CFA and CPA credentials support dual finance/operations mandate
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation posted to CareDx website, current as of Feb 24, 2026
- Reg FD disclosure ensures all investors receive material non-public information simultaneously: presentation may contain strategic or financial updates worth reviewing directly
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CareDx, Inc. 8-K filings
Get the next CDNA 8-K as it lands
Follow CDNA for push alerts, or ask the research agent what this filing means.